![Ronald Cooper](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ronald Cooper
Directeur Général chez
ENGENE THERAPEUTICS INC.
Fortune : 18 500 $ au 31/05/2026
Profil
Ronald Harold Wilfred Cooper is President, Chief Executive Officer & Director at enGene Therapeutics, Inc. since 2024.
Mr. Cooper is Chairman at C4 Therapeutics, Inc. since 2024.
Mr. Cooper was President, Chief Executive Officer & Director at Albireo AB. Mr. Cooper was President, Chief Executive Officer & Director at Albireo Pharma, Inc. from 2016 to 2023.
Mr. Cooper was Independent Director at Genocea Biosciences, Inc. from 2016 to 2021.
Mr. Cooper was Director at Albireo Ltd. from 2016 to 2021.
Mr. Cooper was Independent Director at Generation Bio Co. from 2021 to 2026.
Mr. Cooper was President-Europe at Bristol Myers Squibb Co. from 2010 to 2015.
Mr. Cooper completed undergraduate education at St. Francis Xavier University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ENGENE THERAPEUTICS INC. 0,01 % | 24/04/2026 | 10 000 ( 0,01 % ) | 18 500 $ | 31/05/2026 |
| 22/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Ronald Cooper
| Sociétés | Poste | Début |
|---|---|---|
| C4 THERAPEUTICS, INC. | Président | 07/06/2024 |
| ENGENE THERAPEUTICS INC. | Directeur Général | 21/07/2024 |
Anciens postes connus de Ronald Cooper
| Sociétés | Poste | Fin |
|---|---|---|
| GENERATION BIO CO. | Directeur/Membre du Conseil | 06/02/2026 |
| ALBIREO PHARMA, INC. | Directeur Général | 02/03/2023 |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies that address medical needs in the gastrointestinal and liver disease area | Directeur Général | 01/11/2016 |
| GENOCEA BIOSCIENCES, INC. | Directeur/Membre du Conseil | 12/04/2021 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2015 |
Formation de Ronald Cooper
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
61
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Genocea Biosciences, Inc.
 Genocea Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that discovers and develops novel cancer immunotherapies | Health Technology |
St. Francis Xavier University
 St. Francis Xavier University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies that address medical needs in the gastrointestinal and liver disease area | Health Technology |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Develops bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders | Health Technology |
C4 Therapeutics, Inc.
 C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets novel bile acid modulators for liver and gastrointestinal diseases and disorders | Health Technology |
Generation Bio Co.
 Generation Bio Co. Pharmaceuticals: MajorHealth Technology Develops and commercializes genetic medicines | Health Technology |
enGene Holdings, Inc.
 enGene Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that develops, manufactures and sells non-viral genetic medicines | Commercial Services |
